| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $560,238 ) |
| | 2024 | 2024 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 000 | 4 | NIH | 6/28/2024 | $560,238 |
|
| Issue Date FY: 2023 ( Subtotal = $627,160 ) |
| | 2023 | 2023 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 001 | 3 | NIH | 8/31/2023 | $577,160 |
| | 2023 | 2023 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 002 | 3 | NIH | 9/2/2023 | $50,000 |
| | 2023 | 2020 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 000 | 2 | NIH | 5/3/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $40,000 ) |
| | 2022 | 2022 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 001 | 2 | NIH | 9/7/2022 | $40,000 |
| | 2022 | 2020 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 000 | 2 | NIH | 7/21/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $734,548 ) |
| | 2021 | 2020 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 001 | 2 | NIH | 3/23/2021 | $598,926 |
| | 2021 | 2020 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 002 | 2 | NIH | 3/24/2021 | $0 |
| | 2021 | 2020 | HOAG MEMORIAL HOSPITAL PRESBYTERIAN | 1 HOAG DR | NEWPORT BEACH | CA | 92663-4162 | ORANGE | USA | R01CA248398 | CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS | 004 | 2 | NIH | 4/22/2021 | $135,622 |
|
|
